|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12345678910111213...10631064» |
- Sarclisa (isatuximab-irfc) / Sanofi
CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB -DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: AN ITALIAN REAL-LIFE MULTI-CENTER RETROSPECTIVE EXPERIENCE (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_668;
Our real-world experience indicates that isa-KD is a viable treatment option even for high-risk patients, including those with high genetic risk, extramedullary disease, lenalidomide refractoriness, and prior anti-CD38 exposure. These high-risk patients remain a clinical challenge, suggesting that early incorporation of T-cell reconditioning therapies may offer improved prognosis.
- Xpovio (selinexor) / Karyopharm
Effect of Prior Selinexor Exposure on Clinical Outcomes of Chimeric Antigen Receptor T-cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Descriptive Analysis (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_666;
In this retrospective analysis, CAR-T clinical outcomes in heavily pretreated RRMM were unaffected by prior selinexor treatment. Further studies are warranted to examine the effect of specific selinexor combinations on clinical outcomes, including promoting an anti-tumor immune microenvironment, particularly pre-, post- and in-between CAR-T and other T-cell engaging regimens.
- Darzalex (daratumumab) / J&J, Blenrep (belantamab mafodotin-blmf) / GSK
A deeper look into infections among myeloma patients treated with Daratumumab or Belantamab mafodotin (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_664;
Nevertheless, infections including CMV reactivation are frequent adverse events associated with antiCD38 but rare among anti-BCMA immunotherapies utilized in analysis. Intravenous Immunoglobulin use per treatment year was less among patients treated with Belantamab.
- Xpovio (selinexor) / Karyopharm
Novel selinexor triplet and quadruplet regimens (SNd, SPEd, SBd, SDPd): Results from the Phase 1b/2 STOMP multiple myeloma trial (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_663;
P1/2
The majority of pts tolerated the selinexor regimens at the intended dosing. No increase in partner drug toxicities were observed, which aligns with the combinability profile of S + d with carfilzomib (SKd), P (SPd), and D (SDd) in the STOMP study.
- Ninlaro (ixazomib) / Takeda
IXAZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_662;
Similar outcomes were also reported in RR MM group of patients by other RWE analyses. There are some discrepancies between RWE data and data reported in clinical trials.
- dexamethasone / Generic mfg.
A retrospective study of serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors treatments (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_659;
Patients with varying levels of Scr and AST exhibited divergent clinical outcomes. Consequently, in the era of PIs, transplant therapies remain efficacious for MM patients.
- Darzalex (daratumumab) / J&J
Impact of weekly versus twice weekly bortezomib on rates of peripheral neuropathy in combination with lenalidomide, dexamethasone and daratumumab (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_658;
Further analysis is needed in this context to prospectively evaluate weekly versus twice weekly bortezomib. It is important to advocate for intensity modification in future clinical trials.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
Bortezomib thalidomide dexamethasone as first-line treatment in Newly Multiple Myeloma Patients in Per (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_652;
Bortezomib thalidomide dexamethasone is highly effective in patients with newly diagnosed multiple myeloma which is similar to international literature. Overall survival is good compared to other reports; however, the lack of the availability FISH test is very important to stratify our patient in order to give a better treatment.
- Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Stem Cell (SC) Yield and Transplant with Daratumumab (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_649;
P3
Despite D-VRd ind therapy resulting in a lower SC yield compared to VRd alone, SC mobilization and collection remained feasible with D-VRd ind. Overall, successful transplantation was achieved in pts with TE NDMM when combining DARA with VRd ind and when performed after Cycle 6.
- Darzalex (daratumumab) / J&J
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-eligible Patients With Multiple Myeloma: A Pooled Analysis of Patients Aged ?65 Years From Both PERSEUS and GRIFFIN Studies (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_644;
D-VRd ind/consol and D-R maint led to improved PFS and MRD neg vs VRd/R in TE NDMM pts aged ?65 yrs. These data support D-VRd/D-R as a standard of care and highlight the benefit of DARA during ind/consol and maint for all TE pts with NDMM, regardless of age.
- Darzalex (daratumumab) / J&J
A Real-World Study to Assess Treatment Patterns of Patients with 2L+ Relapsed or Refractory Multiple Myeloma in Italy, Germany, and the United Kingdom (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_643;
Following regulatory approvals of the MAIA dara + len + dex regimen, it is likely that 1L use of this combination will increase over time, potentially increasing the proportion of pts refractory to len-based treatments. Due to variations in pt profiles observed across countries, results at a country level may not be generalizable to the overall MM population.
- Darzalex (daratumumab) / J&J
IMPACT OF DARATUMUMAB/BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (DVTD) INDUCTION THERAPY ON CHEMO-FREE STEM CELL MOBILIZATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL LIFE EXPERIENCE (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_641;
Due to variations in pt profiles observed across countries, results at a country level may not be generalizable to the overall MM population. Plerixafor (Plx) 240
- Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_639;
Use of post-transplant maintenance was associated with significantly better outcomes. These results may further improve in the future with the use of quadruplet induction and MRD-guided maintenance.
- Sarclisa (isatuximab-irfc) / Sanofi
Stem-Cell Mobilization and Transplantation in Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib-Lenalidomide-Dexamethasone With or Without Isatuximab: Results From the IsKia Trial (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_635;
These results may further improve in the future with the use of quadruplet induction and MRD-guided maintenance. Pts received 4 28-day induction cycles with Isa-KRd vs KRd and subsequently started SC mobilization 4
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Impact of Obesity on Outcomes of Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_634;
In a large cohort of patients undergoing auto-HCT for MM, elevated BMI was not associated with a significant difference in survival outcomes. Our findings suggest that obesity may not be a significant determinant in auto-HCT eligibility for myeloma patients.
- A single-arm prospective study of the combination of KAPD induction with or without ASCT and KP maintenance for newly diagnosed extramedullary multiple myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_626;
KAPD as a induction regimen is safe and facilitates profound responses in patients with newly-diagnosed EMM. The study is ongoing, longer follow-up is needed to evaluate safety and efficacy of the comprehensive treatment approach with KAPD induction, with or without ASCT and carfilzamib/pomalidomide maintenance for newly diagnosed EMM.
- Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_622;
The study is ongoing, longer follow-up is needed to evaluate safety and efficacy of the comprehensive treatment approach with KAPD induction, with or without ASCT and carfilzamib/pomalidomide maintenance for newly diagnosed EMM. Overall, 45 (91.8%) pts underwent stem cell mobilization (plerixafor given in 40.8%), with a median (range) stem cell yield of 5.7 (2.3-15.0)
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
Iberdomide is immune stimulatory and induces deep anti-myeloma activity across doses in combination with daratumumab in patients with TNE NDMM from the CC-220-MM-001 study (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_617;
P1/2
Notably, data showed significant overlap across doses suggesting all 3 doses of IBER tested are biologically active in combination with DARA + DEX. These data support the use of IBER at doses of 1.0 mg or higher in combination with DARA to achieve maximal pharmacodynamic effects.
- Darzalex (daratumumab) / J&J
REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_609;
Response rates demonstrate clinical benefit, with a similar follow-up between the CASSIOPEIA trial and the present study, the PFS and OS data being similar, as well. A longer follow-up is necessary to demonstrate an advantage of lenalidomide maintenance in this setting.
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
Phase 1b/2 trial of iberdomide in combination with daratumumab, dexamethasone +/- carfilzomib to eliminate MRD after induction therapy and ASCT in NDMM (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_608;
Iber-Dd and Iber-DKd are safe combinations and able to eliminate MRD persistent after modern induction therapy and ASCT in NDMM. This study is ongoing, complete safety and efficacy results from part 1 and updated results from part 2 will be presented at the meeting.
- Ninlaro (ixazomib) / Takeda
In-class transition from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Updated 3-year PFS analysis of US MM-6 overall and by patient (pt) subgroups of interest (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_607;
P4
The expected decrement in outcomes associated with older, frail, and RCT-ineligible pts was observed; however, these results were not meaningfully different. Long-term triplet consolidation with IRd may provide an alternative approach to induction/maintenance for community-based NDMM pts who are not eligible for upfront transplantation, including those who are older, frail, and/or have comorbidities.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
VRd dosing and outcomes in Indian patients with Newly diagnosed Multiple Myeloma: Report from a propsepctive Clinical study (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_605;
Dose modification did not adversely affect the myeloma outcomes at an early time point however a longer follow up is needed. This analysis suggests considering appropriate dose modification in Indian patients for optimal outcomes.
- Darzalex (daratumumab) / J&J
Real-World Evidence of Proteasome Inhibitors, Immunomodulatory Drugs and Anti-CD38 in Patients with Multiple Myeloma Treated in Brazil: TOTEMM-B Study Insights (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_602;
However, use of lenalidomide was slightly lower compared with use in developed countries, probably due to later (2017) regulatory approval and barriers to reimbursement in Brazil. A similar pattern was observed for the use of daratumumab as 1L therapy.
- Darzalex (daratumumab) / J&J
A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_600;
This highlights the need for better supportive care strategies. For all regimens, real world R dosing is lower compared to the clinical trial setting.
- Darzalex (daratumumab) / J&J
Daratumumab combined with carfilzomib and dexamethasone as an induction regimen results in rapid response in newly diagnosed POEMS syndrome (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_599;
For all regimens, real world R dosing is lower compared to the clinical trial setting. Anti-plasma cell-based regimen and ASCT to treat POEMS syndrome can achieve good response, Dara +KD can result in rapid response.
- Darzalex (daratumumab) / J&J
A retrospective analysis of the efficacy and safety of a single-center daltuzumab-based treatment for light chain amyloidosis (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_598;
At the same time, the adverse reactions were slightly controllable. It shows that Daratumumab is an effective treatment option for AL patients, which provides an important treatment reference and basis for clinicians when facing AL patients with poor basic conditions.
- Darzalex (daratumumab) / J&J, Rituxan (rituximab) / Roche
Plasmacytoma-like Posttransplant Lymphoproliferative Disorder in a Young Kidney Transplant Recipient (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_595;
It shows that Daratumumab is an effective treatment option for AL patients, which provides an important treatment reference and basis for clinicians when facing AL patients with poor basic conditions. Treatment included reduction of immunosuppression by discontinuing azathioprine, followed by 8 cycles of bortezomib
- dexamethasone / Generic mfg.
Evaluating the Efficacy and Safety of Limiting Dexamethasone in Newly Diagnosed AL Amyloidosis Compared to Conventional Dosing (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_583;
Our findings indicate that limiting dexamethasone usage in newly diagnosed AL amyloidosis patients maintains effective hematologic and organ response rates compared to conventional duration while significantly reducing the risk of adverse events, including life-threatening toxicities. By updating guidelines to support early discontinuation of steroids, we can enhance patient safety without compromising treatment success.
- Darzalex (daratumumab) / J&J
A unique presentation of Light Chain Deposition Disease: kidney disease with no proteinuria (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_578;
The kidney injury is primarily caused by the abnormal deposition or activity of monoclonal proteins in the kidney, including, light chains, heavy chains, or intact immunoglobulins, produced by small, nonmalignant or premalignant plasma cell or B cell clones. Patients with LCDD usually have abnormal FLC ratio, hematuria and proteinuria ?1.5g/day.
- Darzalex (daratumumab) / J&J
SYSTEMIC AMYLOIDOSIS WITH GASTROINTESTINAL INVOLVEMENT: LOW SUSPICIOUS PRESENTATION, LATE TREATMENT, MULTIORGAN DISFUNCTION AND HIGHER THE RISK OF DEATH AFTER AUTOLOGOUS STEM CELL TRANSPLANT. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_576;
The lack of a risk score to estimate massive bleeding in GI involvement makes the management of these patients more difficult. This case had a late diagnose of systemic amyloidosis with GI, cardiac, hepatic and renal involvement.
- Darzalex (daratumumab) / J&J
Outcomes of incorporating IV Daratumumab for the treatment of AL amyloidosis in real world patients from a multicenter registry in Latin America (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_572;
P=N/A
This study is relevant since it is a real life study, in which intravenous daratumumab was used since the subcutaneous formulation is not available in most Latin American countries and also included patients with advanced cardiaca stages. Treatment with Daratumumab should be considered a therapy of choice in AL amyloidosis.
- dexamethasone / Generic mfg., melphalan / Generic mfg., carfilzomib / Generic mfg.
Identifying Anti-Viral Drugs to Sensitize and Re-Sensitize MM Cells to Chemotherapy (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_568;
These observations strongly suggest that EV and DV, which alone are non-toxic to MM or normal cells have a broad effect in sensitizing MM cells to different chemo-drugs, re-sensitize chemo-refractory MM cells to chemotherapies; and can reduce the doses of chemo-drugs to minimize the side effects of chemotherapy in patients. Our results provide the justification and tools for developing novel and effective strategies for targeting both MM drug efflux to improve the therapeutic efficacy of chemotherapy.
- Blenrep (belantamab mafodotin-blmf) / GSK
How to effectively administer belantamab mafodotin: Knowledge gained from the phase 1/2 BelaRd study in newly diagnosed transplant-ineligible patients with multiple myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_566;
To reduce peak toxicities, manifesting even with the extended dosing interval, dose reduction should be considered. High-grade cataract should be treated early, as it is a common problem in these pts that confers an additional risk for visual acuity decline.
- Darzalex (daratumumab) / J&J
Autologous transplantation is the strongest prognostic factor for overall survival in Multiple Myeloma patients with deletion 17p: 20-year Real-World experience of the Greek Myeloma Study Group. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_513;
We conclude that, in the real-world setting, del17p remains an independent prognostic factor for OS, surpassing the predictive value of other high-risk abnormalities. For patients with del17p, neither baseline prognostic markers/staging systems or current upfront regimens predicted for OS; ASCT remains a strong prognosticator underscoring its established therapeutic value in this high-risk population.
- Sarclisa (isatuximab-irfc) / Sanofi
MRD tracking in blood using a de novo sequencing from SPEP gel of M-protein in Multiple Myeloma Patients (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_471;
P1
Identical M-protein sequenced from the gel and directly from serum demonstrates the specificity and robustness of M-inSight in serum. The separation in gel allows an alternative sample preparation for M-protein sequencing.
- Darzalex (daratumumab) / J&J
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_467;
The separation in gel allows an alternative sample preparation for M-protein sequencing. This study highlights the factors that contribute to the reappearance of MRD in transplant-eligible NDMM patients and emphasizes the importance of early attainment of MRD-negative status and maintenance therapy options to maintain long-term MRD negativity.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Real-world minimal residual disease testing patterns: findings from the Connect (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_466;
P
Most commonly, the MRD tests were carried out during the first line of therapy (41.2%), with lenalidomide, bortezomib plus dexamethasone (RVd) being the most common regimen (16.0%) received by pts in the line where the MRD test was conducted. This analysis of pts in the Connect MM Registry provides the largest dataset of real-world MRD testing patterns available to date, with enrollment from 2009
- dexamethasone / Generic mfg.
Gut microbiota differences among transplant ineligible patients with newly-diagnosed multiple myeloma treated with dara-len-dex (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_454;
The results of this study suggests that the gut microbiome of patients with MM initiating treatment with dara-len-dex is notably influenced by the frailty status of the patients. Further follow up is ongoing to understand the impact of this frailty-microbiome association on both toxicity and disease progression in MM.
- Central Nervous System Involvement in Multiple Myeloma Cases Reported at Instituto Nacional de Cancerolog (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_441;
Progression of the disease occurred in 83% of the patients, consequently an evaluation for subsequent response to the chemotherapy regimens was not possible. Different types of treatment schemes were prescribed; mainly systemic chemotherapy, followed by intrathecal and in some cases radiotherapy.
- Talvey (talquetamab-tgvs) / J&J
Oral Symptom Assessment using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients treated with Talquetamab (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_438;
Oral specific PROs demonstrated a significant worsening of oral symptoms, global health status with Tal by week 2 followed by an improvement in global health status. Oral symptoms improved by 3 months in those stopping.
- Clinical (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_436;
Previous studies have demonstrated differences in the quality of care for Multiple Myeloma patients due to socioeconomic disparities. Our study enlightens the inequity in access to diagnostic tests for better prognostic stratification and novel therapies between these 2 private and public hospitals, what reflects the macro scenario in Brazil, highlighting
- Risk and incidence of venous thromboembolism in newly diagnosed Multiple Myeloma patients (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_434;
In summary, our cohort had overall a low risk as well as low incidence for developing a VTE as compared to Western population. The risk scores had little utility given that most events occurred in low or intermediate risk rather than high risk score groups.
- melphalan / Generic mfg.
CHEMOTHERAPY RELATED NAUSEA AND VOMITING PROPHYLAXIS WITH APREPITANT FOR PATIENTS RECEIVING HIGH DOSE MELPHALAN FOLLOWED BY HSCT: A COST UTILITY ANALYSIS (CUA) (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_410;
A combination of aprepitant, granisentron and dexamethasone is more efficacious than the combination of only anti 5-HT and corticosteroids. The result of the present CUA suggest that aprepitant is cost-effective for the prevention of CINV given a commonly accepted willingness to pay threshold of R$ 100.000/QALY.
- Sarclisa (isatuximab-irfc) / Sanofi
An orthopedic consultation and exercise intervention in patients with multiple myeloma during induction therapy: the randomized controlled GMMG-HD8-INDEX trial (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_407;
Our first results indicate that an exercise intervention based on an orthopedic evaluation of bone stability is safe during induction therapy for patients with newly-diagnosed MM. However, patients need to be monitored closely and exercise plans should be adapted to individual clinical conditions.
- Darzalex (daratumumab) / J&J
Guillain-Barr (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_406;
We present the case of a 65-year-old patient with a previous history of ischemic heart disease, treated for a lambda light chain ISS1 MM who achieved VGPR after 4 induction cycles of daratumumab-bortezomib-lenalidomide-dexamethasone, but who complained of bortezomib-induced sensory polyneuropathy. This case underscores a rare autoimmune neurological complication of stem cell transplantation, prompting inquiries into diagnosis, appropriate management, especially in highly immunocompromised patients, and presenting confounding factors.
- Darzalex (daratumumab) / J&J, Cytovene (ganciclovir) / Roche
GASTROINTESTINAL HISTOPLASMOSIS IN A PATIENT WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION: ORAL ULCER DIFFERENTIAL DIAGNOSIS. CASE REPORT. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_405;
We report a case of gastrointestinal histoplasmosis infection in a Myeloma patient after autologous stem cell transplant and DVD treatment. Thus, we recall the attention for the importance of histoplasmosis suspicion as a differential diagnosis in patients undergoing stem cell transplant and possibly the impact of new immunotherapies for MM treatment.
- dexamethasone / Generic mfg.
Ocular complications are common in patients with multiple myeloma receiving dexamethasone: Results of a cross-sectional patient survey (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_400;
Consistent with previous findings (Banerjee AJH 2024), higher dex doses are associated with greater rates of cataracts; however, dex dosing did not impact patient-reported rates of glaucoma. Blepharitis, often thought to be a rare toxicity of bortezomib, was reported by almost a quarter of patients even if bortezomib-unexposed.
- Carvykti (ciltacabtagene autoleucel) / J&J
Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1 (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_394;
P3
Blepharitis, often thought to be a rare toxicity of bortezomib, was reported by almost a quarter of patients even if bortezomib-unexposed. Introduction: The phase 3 CARTITUDE-4 trial (NCT04181827) in patients (pts) with lenalidomide (len)
- Carvykti (ciltacabtagene autoleucel) / J&J
Infections and Immune Reconstitution in the Phase 3 CARTITUDE-4 Trial of Ciltacabtagene Autoleucel vs Standard Care in Patients with Lenalidomide-Refractory Multiple Myeloma (MM) and 1 (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_388;
P3
Introduction: The phase 3 CARTITUDE-4 trial (NCT04181827) in patients (pts) with lenalidomide (len) Cilta-cel arm pts underwent apheresis, received bridging tx (daratumumab-pomalidomide-dexamethasone [DPd]/pomalidomide-bortezomib-dexamethasone [PVd]), and then cilta-cel infusion 5
- Talvey (talquetamab-tgvs) / J&J
Prophylactic Interventions for Oral Toxicities With the GPRC5D (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_365;
Pts will be randomized to 1 of 4 cohorts: 1 control cohort and 3 experimental cohorts receiving the following prophylaxis: dexamethasone mouthwash, oral pregabalin, or clonazepam orally dissolving tablets. This study will provide needed data on smell- and taste-related assessment tools; potential strategies to manage, prevent, and decrease the severity of tal-related oral toxicities; and assessments of the potential impact of toxicities on pt treatment experience.